{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:38:57Z","timestamp":1789609137279,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010249","name":"School of Medicine, Indiana University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010249","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ncl.2020.09.007","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T22:12:08Z","timestamp":1604700728000},"page":"133-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Update in the Management of Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome"],"prefix":"10.1016","volume":"39","author":[{"given":"Cynthia","family":"Bodkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Pascuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ncl.2020.09.007_bib1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1017\/cjn.2017.253","article-title":"Autoantibodies to Low-Density Lipoprotein Receptor-Related Protein 4 in Double Seronegative Myasthenia Gravis: A Systematic Review","volume":"45","author":"Bacchi","year":"2018","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.ncl.2020.09.007_bib2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ncl.2020.09.007_bib3","doi-asserted-by":"crossref","first-page":"e91816","DOI":"10.1371\/journal.pone.0091816","article-title":"Autoantibodies to agrin in myasthenia gravis patients","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ncl.2020.09.007_bib4","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/WNL.0000000000000478","article-title":"Anti-agrin autoantibodies in myasthenia gravis","volume":"82","author":"Gasperi","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.007_bib5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.24769","article-title":"Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial","volume":"53","author":"Benatar","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2020.09.007_bib6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A\u00a0clinical therapeutic trial of cyclosporine in myasthenia gravis","volume":"681","author":"Tindall","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ncl.2020.09.007_bib7","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.007_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1345\/aph.1G501","article-title":"Mycophenolate mofetil treatment of myasthenia gravis","volume":"40","author":"Cahoon","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ncl.2020.09.007_bib9","first-page":"2191","article-title":"Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis","volume":"264","author":"Wang","year":"2017","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.ncl.2020.09.007_bib10","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2020.09.007_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A\u00a0randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.007_bib12","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2020.09.007_bib13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2020.09.007_bib14","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.007_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: A systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2020.09.007_bib16","first-page":"699","article-title":"High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria","volume":"266","author":"Topakian","year":"2019","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.ncl.2020.09.007_bib17","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","article-title":"Rituximab in AChR subtype of myasthenia gravis: systematic review","volume":"91","author":"Di Stefano","year":"2020","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2020.09.007_bib18","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/jca.21377","article-title":"Maintenance plasma exchange treatment for muscle specific kinase antibody positive myasthenia gravis patients","volume":"30","author":"Yamada","year":"2015","journal-title":"J\u00a0Clin Apher"},{"key":"10.1016\/j.ncl.2020.09.007_bib19","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/jca.21694","article-title":"Excellent response to therapeutic plasma exchange in myasthenia gravis patients irrespective of antibody status","volume":"34","author":"Usmani","year":"2019","journal-title":"J\u00a0Clin Apher"},{"key":"10.1016\/j.ncl.2020.09.007_bib20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jocn.2019.08.113","article-title":"Efficacy and tolerability of subcutaneously administered immunoglobulin in myasthenia gravis: A systematic review","volume":"72","author":"Adiao","year":"2020","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.ncl.2020.09.007_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CND.0000000000000119","article-title":"Human immunoglobulin versus plasmapheresis in Guillain-Barre syndrome and myasthenia gravis: a meta-analysis","volume":"18","author":"Ortiz-Salas","year":"2016","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"key":"10.1016\/j.ncl.2020.09.007_bib22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.007_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2013.10.043","article-title":"Maintenance IVIg therapy in myasthenia gravis does not affect disease activity","volume":"338","author":"Hellmann","year":"2014","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.ncl.2020.09.007_bib24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s13760-016-0689-z","article-title":"A\u00a0comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients","volume":"117","author":"Alipour-Faz","year":"2017","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.ncl.2020.09.007_bib25","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/mus.25552","article-title":"Exercise in myasthenia gravis: A feasibility study of aerobic and resistance training","volume":"56","author":"Rahbek","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2020.09.007_bib26","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1212\/WNL.27.12.1103","article-title":"A\u00a0treatment carol: thymectomy revisited","volume":"27","author":"McQuillen","year":"1977","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.007_bib27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized Trial of Thymectomy in Myasthenia Gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ncl.2020.09.007_bib28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","volume":"18","author":"Wolfe","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2020.09.007_bib29","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1212\/WNL.0000000000009294","article-title":"Practice advisory: thymectomy for myasthenia gravis (practice parameter update): report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology","volume":"94","author":"Gronseth","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.007_bib30","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s10072-017-3058-7","article-title":"Thymectomy is a beneficial therapy for patients with non-thymomatous ocular myasthenia gravis: a systematic review and meta-analysis","volume":"38","author":"Zhu","year":"2017","journal-title":"Neurol Sci"},{"key":"10.1016\/j.ncl.2020.09.007_bib31","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.007_bib32","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","article-title":"Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis","volume":"10","author":"Gable","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ncl.2020.09.007_bib33","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/mus.24254","article-title":"Complications of radiologic contrast in patients with myasthenia gravis","volume":"50","author":"Mehrizi","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2020.09.007_bib34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ncl.2020.09.007_bib35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.ncl.2020.09.007_bib36","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/WCO.0000000000000736","article-title":"The congenital myasthenic syndromes: expanding genetic and phenotypic spectrums and refining treatment strategies","volume":"32","author":"Vanhaesebrouck","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.ncl.2020.09.007_bib37","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/ana.10477","article-title":"Oculobulbar involvement is typical with Lambert-Eaton myasthenic syndrome","volume":"53","author":"Burns","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2020.09.007_bib38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/WNO.0000000000000258","article-title":"Lambert-Eaton Myasthenic syndrome: ocular signs and symptoms","volume":"36","author":"Young","year":"2016","journal-title":"J\u00a0Neuroophthalmol"},{"key":"10.1016\/j.ncl.2020.09.007_bib39","first-page":"A31","article-title":"Neuronal autoantibodies and paraneoplastic neurological syndromes associated with extrapulmonary small cell carsinoma","volume":"48","author":"Kennelly","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.007_bib40","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1212\/01.wnl.0000281663.81079.24","article-title":"SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome","volume":"70","author":"Sabater","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.007_bib41","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ncl.2018.01.008","article-title":"Lambert-Eaton Myasthenic Syndrome","volume":"36","author":"Kesner","year":"2018","journal-title":"Neurol Clin"},{"key":"10.1016\/j.ncl.2020.09.007_bib42","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1212\/WNL.0000000000003794","article-title":"Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome","volume":"88","author":"Maddison","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.007_bib43","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","article-title":"3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome","volume":"321","author":"McEvoy","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ncl.2020.09.007_bib44","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/mus.25070","article-title":"Amifampridine phosphate (Firdapse((R))) is effective and safe in a phase 3 clinical trial in LEMS","volume":"53","author":"Oh","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2020.09.007_bib45","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/mus.26052","article-title":"3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia","volume":"57","author":"Sanders","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2020.09.007_bib46","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/mus.25009","article-title":"Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine","volume":"53","author":"Burns","year":"2016","journal-title":"Muscle Nerve"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861920300748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861920300748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:17:59Z","timestamp":1760005079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861920300748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0733861920300748"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2020.09.007","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update in the Management of Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2020.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}